Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ATR-IN-11 (Compound Hit01) is a potent inhibitor of ataxia capillaris and Rad3-related (ATR) kinases. ATR-IN-11 is a promising lead compound for the discovery of subsequent drugs targeting the ATR kinase, a key regulatory protein in the DNA damage response (DDR) responsible for sensing replication stress (RS). ATR-IN-11 has potential for cancer disease research.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 1,520.00 | |
50 mg | 10-14 weeks | $ 1,980.00 | |
100 mg | 10-14 weeks | $ 2,500.00 |
Description | ATR-IN-11 (Compound Hit01) is a potent inhibitor of ataxia capillaris and Rad3-related (ATR) kinases. ATR-IN-11 is a promising lead compound for the discovery of subsequent drugs targeting the ATR kinase, a key regulatory protein in the DNA damage response (DDR) responsible for sensing replication stress (RS). ATR-IN-11 has potential for cancer disease research. |
Molecular Weight | 446.54 |
Formula | C25H30N6O2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.